Detalhe da pesquisa
1.
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study.
Ann Rheum Dis
; 82(4): 496-506, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36600178
2.
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.
Rheumatology (Oxford)
; 62(2): 606-616, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35766811
3.
Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data.
Rheumatology (Oxford)
; 62(10): 3382-3390, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36810788
4.
Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort.
Clin Exp Rheumatol
; 41(3): 735-743, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36226614
5.
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).
Ann Rheum Dis
; 81(3): 359-369, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34819273
6.
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study.
Ann Rheum Dis
; 81(6): 823-830, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35210262
7.
Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.
Ann Rheum Dis
; 80(11): 1419-1428, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34162594
8.
Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials.
Rheumatol Ther
; 11(2): 457-474, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38416392
9.
Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study.
Arthritis Res Ther
; 25(1): 100, 2023 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37296456
10.
Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA.
RMD Open
; 9(1)2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37001920
11.
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.
Arthritis Res Ther
; 25(1): 109, 2023 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37353788
12.
Risk Management Plans: reassessment of safety concerns based on Good Pharmacovigilance Practices Module V (Revision 2)-a company experience.
J Pharm Health Care Sci
; 8(1): 14, 2022 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35509028
13.
Corrigendum to: Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden.
Rheumatol Adv Pract
; 5(1): rkab005, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33604506
14.
Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden.
Rheumatol Adv Pract
; 4(2): rkaa070, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33409449
15.
Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database.
Clin Drug Investig
; 40(11): 1021-1040, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32779120
16.
Effectiveness of the golimumab educational program in ensuring healthcare professionals' awareness of risks described in the European risk management plan.
Ther Adv Drug Saf
; 10: 2042098619847420, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31205675
17.
Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation.
J Leukoc Biol
; 77(3): 321-7, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15591125
18.
Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages.
J Leukoc Biol
; 71(4): 597-602, 2002 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-11927645
19.
Alternatively activated macrophages during parasite infections.
Trends Parasitol
; 20(3): 126-33, 2004 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15036034
20.
Alternatively activated myeloid cells limit pathogenicity associated with African trypanosomiasis through the IL-10 inducible gene selenoprotein P.
J Immunol
; 180(9): 6168-75, 2008 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18424738